Drugmaker concerned over access to new drugs
NICE unconvinced by survival data from Ipsen and Sanofi drugs
Only five drugs left to assess from old scheme.
Abraxane finally gets NHS funding following price cut.
Cancer Drugs Fund could cover costs in first line use.
Discount swings NICE decision, drug will compete with GSK rival